Skip to main content
Top
Published in: Tumor Biology 3/2015

01-03-2015 | Review

Mutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis

Authors: Huimin Hu, Yanwei Liu, Tao Jiang

Published in: Tumor Biology | Issue 3/2015

Login to get access

Abstract

Cancer is the greatest challenge to human health in our era. Perturbations of receptor tyrosine kinase (RTK) function contribute to a large chunk of cancer etiology. Current evidence supports that mutations in RTKs mediate receptor dimerization and result in ligand-independent kinase activity and tumorigenesis, indicating that mutation-introduced receptor dimerization is a critical component of oncogenesis RTK mutations. However, there are no specialized reviews of this important principle. In the current review, we discuss the physiological and harmless RTK function and subsequently examine mutation-introduced dimerization of RTKs and the role of these mutations in tumorigenesis. We also summarize the protein structure characteristics that are important for dimerization and introduce research methods and tools to predict and validate the existence of oncogenic mutations introduced by dimerization in RTKs.
Literature
2.
go back to reference Schlessinger J, Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron. 1992;9(3):383–91.CrossRefPubMed Schlessinger J, Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron. 1992;9(3):383–91.CrossRefPubMed
3.
go back to reference Assoian RK, Schwartz MA. Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev. 2001;11(1):48–53.CrossRefPubMed Assoian RK, Schwartz MA. Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev. 2001;11(1):48–53.CrossRefPubMed
5.
6.
go back to reference Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda). 2010;25(2):85–101.CrossRef Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda). 2010;25(2):85–101.CrossRef
7.
8.
go back to reference Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61(2):203–12.CrossRefPubMed Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61(2):203–12.CrossRefPubMed
9.
go back to reference Maleszka R, Mason PH, Barron AB. Epigenomics and the concept of degeneracy in biological systems. Brief Funct Genomics. 2014;13(3):191–202.CrossRefPubMed Maleszka R, Mason PH, Barron AB. Epigenomics and the concept of degeneracy in biological systems. Brief Funct Genomics. 2014;13(3):191–202.CrossRefPubMed
10.
go back to reference Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 1988;241(4861):42–52.CrossRefPubMed Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 1988;241(4861):42–52.CrossRefPubMed
11.
go back to reference Locascio LE, Donoghue DJ. KIDs rule: regulatory phosphorylation of RTKs. Trends Biochem Sci. 2013;38(2):75–84.CrossRefPubMed Locascio LE, Donoghue DJ. KIDs rule: regulatory phosphorylation of RTKs. Trends Biochem Sci. 2013;38(2):75–84.CrossRefPubMed
12.
go back to reference Yamanashi Y, Tezuka T, Yokoyama K. Activation of receptor protein-tyrosine kinases from the cytoplasmic compartment. J Biochem. 2012;151(4):353–9.CrossRefPubMed Yamanashi Y, Tezuka T, Yokoyama K. Activation of receptor protein-tyrosine kinases from the cytoplasmic compartment. J Biochem. 2012;151(4):353–9.CrossRefPubMed
13.
14.
go back to reference Wong AJ et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987;84(19):6899–903.CrossRefPubMedPubMedCentral Wong AJ et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987;84(19):6899–903.CrossRefPubMedPubMedCentral
15.
go back to reference Jeuken J et al. Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol. 2009;19(4):661–71.CrossRefPubMedPubMedCentral Jeuken J et al. Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol. 2009;19(4):661–71.CrossRefPubMedPubMedCentral
16.
go back to reference Choura M, Rebai A. Receptor tyrosine kinases: from biology to pathology. J Recept Signal Transduct Res. 2011;31(6):387–94.CrossRefPubMed Choura M, Rebai A. Receptor tyrosine kinases: from biology to pathology. J Recept Signal Transduct Res. 2011;31(6):387–94.CrossRefPubMed
18.
go back to reference Amicone L et al. Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO J. 1997;16(3):495–503.CrossRefPubMedPubMedCentral Amicone L et al. Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO J. 1997;16(3):495–503.CrossRefPubMedPubMedCentral
19.
20.
go back to reference Rodrigues GA, Park M. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol. 1993;13(11):6711–22.CrossRefPubMedPubMedCentral Rodrigues GA, Park M. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol. 1993;13(11):6711–22.CrossRefPubMedPubMedCentral
21.
22.
go back to reference Garrett TP et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 2002;110(6):763–73.CrossRefPubMed Garrett TP et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 2002;110(6):763–73.CrossRefPubMed
23.
go back to reference Cohen-Katsenelson K et al. Identification and analysis of a novel dimerization domain shared by various members of c-Jun N-terminal kinase (JNK) scaffold proteins. J Biol Chem. 2013;288(10):7294–304.CrossRefPubMedPubMedCentral Cohen-Katsenelson K et al. Identification and analysis of a novel dimerization domain shared by various members of c-Jun N-terminal kinase (JNK) scaffold proteins. J Biol Chem. 2013;288(10):7294–304.CrossRefPubMedPubMedCentral
24.
go back to reference Cappellen D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23(1):18–20.CrossRefPubMed Cappellen D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23(1):18–20.CrossRefPubMed
25.
go back to reference Naski MC et al. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet. 1996;13(2):233–7.CrossRefPubMed Naski MC et al. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet. 1996;13(2):233–7.CrossRefPubMed
26.
go back to reference Kannan K, Givol D. FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models. IUBMB Life. 2000;49(3):197–205.CrossRefPubMed Kannan K, Givol D. FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models. IUBMB Life. 2000;49(3):197–205.CrossRefPubMed
28.
go back to reference Roskoski RJ. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res. 2013;68(1):68–94.CrossRefPubMed Roskoski RJ. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res. 2013;68(1):68–94.CrossRefPubMed
29.
go back to reference Stoica GE et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002;277(39):35990–8.CrossRefPubMed Stoica GE et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002;277(39):35990–8.CrossRefPubMed
30.
go back to reference Stoica GE et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem. 2001;276(20):16772–9.CrossRefPubMed Stoica GE et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem. 2001;276(20):16772–9.CrossRefPubMed
31.
go back to reference Shackelford RE et al. ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer. 2014;5(1–2):1–14.PubMedPubMedCentral Shackelford RE et al. ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer. 2014;5(1–2):1–14.PubMedPubMedCentral
32.
go back to reference Takeuchi K et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14(20):6618–24.CrossRefPubMed Takeuchi K et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14(20):6618–24.CrossRefPubMed
33.
go back to reference Lu X, Gross AW, Lodish HF. Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J Biol Chem. 2006;281(11):7002–11.CrossRefPubMed Lu X, Gross AW, Lodish HF. Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J Biol Chem. 2006;281(11):7002–11.CrossRefPubMed
34.
go back to reference Kjaer S et al. Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations. Oncogene. 2006;25(53):7086–95.CrossRefPubMed Kjaer S et al. Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations. Oncogene. 2006;25(53):7086–95.CrossRefPubMed
35.
go back to reference Tong Q, Xing S, Jhiang SM. Leucine zipper-mediated dimerization is essential for the PTC1 oncogenic activity. J Biol Chem. 1997;272(14):9043–7.CrossRefPubMed Tong Q, Xing S, Jhiang SM. Leucine zipper-mediated dimerization is essential for the PTC1 oncogenic activity. J Biol Chem. 1997;272(14):9043–7.CrossRefPubMed
36.
go back to reference Armon A, Graur D, Ben-Tal N. ConSurf: an algorithmic tool for the identification of functional regions in proteins by surface mapping of phylogenetic information. J Mol Biol. 2001;307(1):447–63.CrossRefPubMed Armon A, Graur D, Ben-Tal N. ConSurf: an algorithmic tool for the identification of functional regions in proteins by surface mapping of phylogenetic information. J Mol Biol. 2001;307(1):447–63.CrossRefPubMed
37.
go back to reference Glaser F et al. ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics. 2003;19(1):163–4.CrossRefPubMed Glaser F et al. ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics. 2003;19(1):163–4.CrossRefPubMed
38.
go back to reference Hu J et al. Differential roles of cysteine residues in the cellular trafficking, dimerization, and function of the high-density lipoprotein receptor. SR-BI. Biochemistry. 2011;50(50):10860–75.CrossRefPubMedPubMedCentral Hu J et al. Differential roles of cysteine residues in the cellular trafficking, dimerization, and function of the high-density lipoprotein receptor. SR-BI. Biochemistry. 2011;50(50):10860–75.CrossRefPubMedPubMedCentral
39.
go back to reference Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell. 2004;6(1):75–84.CrossRefPubMed Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell. 2004;6(1):75–84.CrossRefPubMed
40.
go back to reference Zenatti PP et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011;43(10):932–9.CrossRefPubMed Zenatti PP et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011;43(10):932–9.CrossRefPubMed
Metadata
Title
Mutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis
Authors
Huimin Hu
Yanwei Liu
Tao Jiang
Publication date
01-03-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3287-4

Other articles of this Issue 3/2015

Tumor Biology 3/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine